Adaptimmune Therapeutics Plc (id:8224 ADAP)
0.609 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/22/2024 12:52:47 PM)
Exchange open, closes in 3 hours 7 minutes
About Adaptimmune Therapeutics Plc
Market Capitalization 152.25M
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
| Headquarters (address) |
60 Jubilee Avenue Abingdon OX14 4RX United Kingdom |
| Phone | 44 12 3543 0000 |
| Website | https://www.adaptimmune.com |
| Employees | 449 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ADAP |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.421 - 2.05 |
| Market Capitalization | 152.25M |
| P/E trailing | -1.23 |
| P/E forward | -1.57 |
| Price/Sale | 1.08 |
| Price/Book | 3.42 |
| Beta | 2.25 |
| EPS | -0.170 |
| EPS United Kingdom (ID:3, base:637) | 0.430 |